M Ishida1, F Kojima, H Okabe. 1. Department of Clinical Laboratory Medicine and Division of Diagnostic Pathology, Shiga University of Medical Science, Japan.
Abstract
BACKGROUND: Cathepsin K is a cysteine protease with strong collagenolytic and elastolytic properties. Recently, cathepsin K expression in tumour cells of malignant melanoma and in the stromal cells of squamous cell carcinoma of the skin has been reported to play an important role in tumour progression. However, its expression profile in basal cell carcinoma (BCC) has not yet been clarified. OBJECTIVE: The aim of this study is to examine the expression profile of cathepsin K in both the tumour cells and the peritumoural stromal cells of BCC in comparison with its expression in normal skin. METHODS: Fifty consecutive operative cases of BCC, 10 cases of actinic keratosis, 10 cases of Bowen's disease and five normal skin tissues were assessed for cathepsin K expression by immunohistochemical methods. RESULTS: In normal skin, cathepsin K expression was observed in the stratum corneum, mature sebaceous cells and outer root sheath of the hair follicles. Cathepsin K was expressed in the tumour cells of all BCC cases, in which 90% showed diffuse expression (>51% of tumour cells), as well as in the peritumoural stromal cells in all BCC cases. Focal cathepsin K expression was observed in the tumour cells of Bowen's disease (2/10 cases), but not in any of actinic keratosis (0/10 cases). CONCLUSION: Cathepsin K expression may contribute to tumour invasion and peculiar histopathological features, such as fibromucinous stroma around the tumour nests by mediating extracellular matrix degradation in BCC.
BACKGROUND:Cathepsin K is a cysteine protease with strong collagenolytic and elastolytic properties. Recently, cathepsin K expression in tumour cells of malignant melanoma and in the stromal cells of squamous cell carcinoma of the skin has been reported to play an important role in tumour progression. However, its expression profile in basal cell carcinoma (BCC) has not yet been clarified. OBJECTIVE: The aim of this study is to examine the expression profile of cathepsin K in both the tumour cells and the peritumoural stromal cells of BCC in comparison with its expression in normal skin. METHODS: Fifty consecutive operative cases of BCC, 10 cases of actinic keratosis, 10 cases of Bowen's disease and five normal skin tissues were assessed for cathepsin K expression by immunohistochemical methods. RESULTS: In normal skin, cathepsin K expression was observed in the stratum corneum, mature sebaceous cells and outer root sheath of the hair follicles. Cathepsin K was expressed in the tumour cells of all BCC cases, in which 90% showed diffuse expression (>51% of tumour cells), as well as in the peritumoural stromal cells in all BCC cases. Focal cathepsin K expression was observed in the tumour cells of Bowen's disease (2/10 cases), but not in any of actinic keratosis (0/10 cases). CONCLUSION:Cathepsin K expression may contribute to tumour invasion and peculiar histopathological features, such as fibromucinous stroma around the tumour nests by mediating extracellular matrix degradation in BCC.
Authors: Melissa E Rodnick; Xia Shao; Kenneth M Kozloff; Peter J H Scott; Michael R Kilbourn Journal: Nucl Med Biol Date: 2014-02-18 Impact factor: 2.408
Authors: Ethan Walker; Margaret Mann; Kord Honda; Allison Vidimos; Mark D Schluchter; Brian Straight; Matthew Bogyo; Daniel Popkin; James P Basilion Journal: J Am Acad Dermatol Date: 2016-11-19 Impact factor: 11.527
Authors: Magdalena Ciążyńska; Igor A Bednarski; Karolina Wódz; Paweł Kolano; Joanna Narbutt; Michał Sobjanek; Anna Woźniacka; Aleksandra Lesiak Journal: Oncol Lett Date: 2018-07-11 Impact factor: 2.967
Authors: Abhilasha Gupta; Daniela Nitoiu; Donna Brennan-Crispi; Sankar Addya; Natalia A Riobo; David P Kelsell; Mỹ G Mahoney Journal: PLoS One Date: 2015-03-18 Impact factor: 3.240
Authors: Paweł Kolano; Igor A Bednarski; Aleksandra Lesiak; Małgorzata Skibińska; Olga Stasikowska-Kanicka; Marian Danilewicz; Joanna Narbutt Journal: Postepy Dermatol Alergol Date: 2020-05-06 Impact factor: 1.837